Clinical trials: Oral Cavity
Healthy
Bioavailability Study of Isotretinoin Capsules 40 mg Under Fed Condition
To characterise the pharmacokinetic profile of sponsor's test formulation Isotretinoin Capsules 40 mg in comparison to the reference formulation Amnesteem (Containing Isotretinoin) Capsules 40 mg after single oral dose…
- Trial name
- NCT01888224
- Testing
- Isotretinoin
- Where
- India
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Fungemia, Fungal Infections
A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections
The objective of this study is to compare the efficacy and safety between Mycamine and Itraconazole oral solution in preventing invasive fungal infections on autologous(malignant blood diseases) or allogeneic hematopoietic stem…
- Trial name
- NCT00794703
- Testing
- micafungin (Mycamine), itraconazole
- Where
- 10 sites in China
- Volunteers
- 288 people
- Sponsor
- Astellas Pharma Inc
Oral Squamous Cell Carcinoma
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with…
- Trial name
- NCT05893888
- Testing
- PRV211 (Intraoperative Cisplatin System), PRV111 (Cisplatin Transmucosal System), PRV131 (Cisplatin Intratumoral Injectable)
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Privo Technologies
Neoplasm Metastasis
Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours
Open, non-randomized, radiolabelled, single centre study designed to characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg [14C]-radiolabelled AZD2281 (KU-0059436) in patients with advanced…
- Trial name
- NCT00633269
- Testing
- AZD2281
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants
This study will assess how safe ABBV-552 is and how ABBV-552 moves through the body of adult healthy Japanese and Han Chinese participants. Adverse Events will be assessed.
- Trial name
- NCT05686980
- Testing
- ABBV-552
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AbbVie
Cancer
A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
To determine the safety, tolerability and recommended Phase 2 dose of ARQ 197 when administered in combination with erlotinib to patients with advanced solid tumors
- Trial name
- NCT00612703
- Testing
- ARQ 197
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Smoking Cessation
Early Effects of a New Oral Nicotine Replacement Product and NiQuitin™ Lozenge
A comparison of two products for oral nicotine replacement with respect to relief of urges to smoke after single doses of nicotine.
- Trial name
- NCT01075659
- Testing
- Nicotine
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- McNeil AB
Acute Otitis Media
Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media
To evaluate the safety and efficacy of cefdinir oral suspension in children between 6 months and 4 years of age, with acute otitis media, who are at risk of persistent or recurrent otitis media.
- Trial name
- NCT00645203
- Testing
- cefdinir
- Where
- 22 sites in United States, Chile and 5 more
- Volunteers
- 447 people
- Sponsor
- Abbott
Non Small Cell Lung Cancer
TGRX-326 Pharmacokinetic Drug Interaction
This is a drug-drug interaction study for TGRX-326 to evaluate the effects of CYP3A inhibitor/inducer drugs on pharmacokinetic profiles of TGRX-326, an ALK inhibitor indicated for treatment of Non-small cell lung cancer.
- Trial name
- NCT06294561
- Testing
- Itraconazole+TGRX-326, Efavirenz+TGRX-326
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Dentin Sensitivity, Oral Hygiene
A Study Assessing the Effects of an Experimental Dentifrice in Maintaining Tooth Color Following Tooth Bleaching
The main aim of this study is to investigate the ability of an experimental dentifrice containing 5 percent (%) potassium nitrate (KNO3), 1% alumina and 5% sodium tripolyphosphate (STP), to maintain tooth color and reduce…
- Trial name
- NCT06150573
- Testing
- Test Dentifrice, Reference Dentifrice (Aquafresh Cavity Protection)
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- HALEON
Healthy
Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects
Study to assess the amount of BIBR 953 ZW in urine and concentrations in plasma after administration of 50 mg of BIBR 1048 bid over three days each administered as two experimental formulations relative to drinking solution with…
- Trial name
- NCT02170623
- Testing
- BIBR 1048 MS Capsule I, BIBR 1048 MS Capsule K, Pantoprazole
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Castration-resistant Prostate Cancer, CRPC
A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of once-daily (QD) oral dosing of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant…
- Trial name
- NCT02361086
- Testing
- VT-464: given orally once daily in 28 day cycles
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Innocrin Pharmaceutical
Rheumatoid Arthritis
A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart
This study is being performed to investigate the potential for AZD5672 to affect the electrical conduction pathways in the heart.
- Trial name
- NCT00887770
- Testing
- AZD5672, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Arterial Hypertension
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
TripleTRE investigates the effect of initial triple combination therapy (oral endothelin receptor antagonist (ERA) + oral phosphodiesterase tyüe-5 inhibitor (PDE-5i) + parenteral treprostinil) compared to double oral therapy…
- Trial name
- TripleTRE (NCT06317805)
- Testing
- Generic treprostinil sodium + Standard of Care (Double Oral), Standard of Care - Double Oral
- Where
- 28 sites in Argentina, Austria and 10 more
- Volunteers
- 110 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Healthy
A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
The purpose of this study is to assess the bioequivalence of four different lazertinib oral tablet formulations in healthy adult participants under fasted condition.
- Trial name
- NCT05742594
- Testing
- Lazertinib
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis Patients
The primary objective of this study is to evaluate the safety, tolerability and pharmacokinetic (PK) profiles of multiple abdominal subcutaneous injection of GB224 in combination with oral methotrexate in Chinese patients with…
- Trial name
- NCT04179513
- Testing
- GB224 10mg, GB224 20mg
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Genor Biopharma Co., Ltd.
Healthy
YH4808 Postprandial PK/PD Study in Healthy Subjects
A clinical Study to evaluate the safety and pharmacokinetics/pharmacodynamics(PK/PD) of YH4808 after repeated Oral administration and Postprandial state in healthy volunteers
- Trial name
- NCT01761513
- Testing
- YH4808
- Where
- South Korea
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
CoronaVirus Induced Disease-2019 (COVID-19)
Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- iNSPIRE (NCT04375397)
- Testing
- Ibrutinib
- Where
- 9 sites in United States
- Volunteers
- 46 people
- Sponsor
- AbbVie
Chronic Obstructive Pulmonary Disease
Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease
This is an investigation of the beneficial effects, tolerability and safety of a range of single doses of orally inhaled glycopyrronium bromide (PSX1002GB pMDI) in male and female patients with moderate or severe chronic…
- Trial name
- NCT01703624
- Testing
- glycopyrronium bromide
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Prosonix Limited
Type 2 Diabetes Mellitus
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Primary Objective: To demonstrate the superiority of iGlarLixi (fixed ratio combination of insulin glargine and lixisenatide) to insulin glargine on glycemic control as assessed by glycated hemoglobin A1c (HbA1c) change in…
- Trial name
- Lixilan-L-CN (NCT03798080)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin
- Where
- 45 sites in China
- Volunteers
- 426 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.